New markers of early cardiovascular risk in multiple sclerosis patients: Oxidized-LDL correlates with clinical staging

Filipe Palavra\textsuperscript{a,b,*}, Daniela Marado\textsuperscript{c}, Filipa Mascarenhas-Melo\textsuperscript{b}, José Sereno\textsuperscript{b}, Edite Teixeira-Lemos\textsuperscript{d}, Carla Cecília Nunes\textsuperscript{a}, Grilo Gonçalves\textsuperscript{a}, Frederico Teixeira\textsuperscript{b} and Flávio Reis\textsuperscript{b}

\textsuperscript{a}Neurology Department, General Hospital, University and Hospital Centre of Coimbra, Coimbra, Portugal
\textsuperscript{b}Laboratory of Pharmacology and Experimental Therapeutics, IBILI, Medicine Faculty, Coimbra University, Coimbra, Portugal
\textsuperscript{c}Internal Medicine Department, General Hospital, University and Hospital Centre of Coimbra, Coimbra, Portugal
\textsuperscript{d}ESAV and Educational Technologies and Health Study Center, Polytechnic Institute of Viseu, Campus Politécnico, Viseu, Portugal

Abstract.

OBJECTIVES: This study aimed to characterize a population of multiple sclerosis (MS) patients in terms of traditional and new cardiovascular risk factors and assess their putative correlation with clinical disease activity (evaluated by the Expanded Disability Status Scale [EDSS]).

METHODS: Thirty relapsing MS patients and 66 subjects, matched by age and sex, were enrolled in this cross-sectional study. For each subject, anthropometric data were collected and classical biochemical (including lipid profile, glucose and C reactive protein [CRP] levels) and novel markers (paraoxonase 1 [PON1] enzyme activity and contents of high-density lipoprotein [HDL] cholesterol, oxidized low-density lipoprotein [Ox-LDL], tumor necrosis factor [TNF]-alfa, vascular endothelial growth factor [VEGF] and adiponectin) were studied.

RESULTS: In patients group, 23 women and 7 men were included, aged 35.00 (28.25–40.25) years and scoring a median of 2.00 (1.50–3.13) in EDSS. Comparing with controls, the most relevant differences encountered were: increased serum triglycerides \((P<0.001)\), Ox-LDL \((P<0.001)\) as well as Ox-LDL/LDL ratio and reduced small HDL \((P=0.040)\), accompanied by a trend to increased VEGF concentration. LDL content, especially Ox-LDL, showed positive and significant correlation with EDSS \((r=0.458; P=0.011)\) and VEGF \((r=0.453; P=0.014)\).

CONCLUSIONS: MS patients presented a profile of early CV risk, being Ox-LDL contents a putative good marker and having correlation with the clinical activity of the disease.

Keywords: Multiple sclerosis, early cardiovascular risk, EDSS, oxidized-LDL, small HDL, VEGF

1. Introduction

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), being responsi-
tion [6], increased blood pressure and tachycardia [7], ventricular disturbances [8] and impairment of the balance between vasoconstrictors and vasodilators, such as prostaglandins and nitric oxide (NO) [9,10]. However, there is still no clear explanation for all the aspects that may underlie these findings.

Chronic inflammation is also an important factor to be considered in the development of atherosclerosis, also contributing to raise the overall CVR, by several factors. Content and/or lipoproteins functionality may play a role in the development and progression of MS [11]. Paraoxonase 1 (PON1) is an enzyme which is connected to high-density lipoprotein (HDL), thought to be responsible for anti-atherogenic and antioxidant properties of such lipoproteins, giving also protection against oxidized low-density lipoprotein (Ox-LDL) [12]. Several studies have shown a strong relationship between their activity and the development of atherosclerosis. However, its potential involvement in injury and premature atherosclerotic disease in patients with MS remains to be clarified. Moreover, inflammatory imbalances, viewed by increased pro-inflammatory cytokines, such as TNF-α and/or reduced anti-inflammatory and anti-atherogenic molecules, including adiponectin, have been considered key factors for the CVR in other pathologies [13, 14] and deserve attention in MS. A similar effect has been given to the phenomenon of angiogenesis, being the vascular endothelial growth factor (VEGF) a new biomarker with increased importance [15,16].

Based on this background and considering the limited information available on the role of new biomarkers for assessment of cardiometabolic risk, we aimed, with this study, to characterize a population of MS patients in terms of traditional and new CVR factors (and, comparing with controls, identify the more relevant markers in corroborating patients’ higher theoretical vascular risk) and assess their putative correlation with clinical disease activity (evaluated by Kurtzke’s Expanded Disability Status Scale [EDSS]) [17].

2. Materials and methods

2.1. Ethics statement

This study took place after authorization by the Ethics Committee of the University and Hospital Centre of Coimbra and upon obtaining written informed consent from the patient, by filling in a specific document, which was also approved by that Committee. The study was performed in agreement with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

2.2. Study design

This was a single-center, cross-sectional study. Thirty MS patients and 66 healthy volunteers, matched by age and sex, without any known neurological or cardiovascular disease (and functioning as a control group) were enrolled in the study. For each subject, anthropometric data were collected (age, sex, weight, body mass index [BMI], waist circumference and systolic and diastolic blood pressure), classical biochemical (lipid profile, glucose and CRP were also studied and novel cardiometabolic risk markers (PON1 activity, content of Ox-LDL, TNF-α, VEGF and adiponectin) were determined. For MS patients, EDSS rate was also registered, at the day of study enrollment.

2.3. Patient population

The study population included 30 patients with relapsing-remitting MS (RRMS), consecutively enrolled from our MS Clinic, satisfying the following inclusion criteria: 1) to be aged between 18 and 55 years; 2) to be diagnosed with RRMS according to the revised McDonald criteria (2005) [18], for, at least, 6 months; 3) to be under stable treatment with first line immunomodulatory drugs (glatiramer acetate or interferon beta) or natalizumab for, at least, 3 months; 4) to be on fasting condition at the day of blood collection; 5) to have given the informed consent for inclusion in the study. Patients with the following conditions were excluded: 1) those who had a history of MS relapse in the last 3 months; 2) those who were submitted to corticosteroid treatment in the last 3 months; 3) those who have a history of autoimmune and inflammatory diseases, beyond MS; 4) those patients who had a clinical and laboratorial documentation of infection in the last 3 months. Patients were under the following treatments: interferon beta-1a (n = 10); interferon beta-1b (n = 8); glatiramer acetate (n = 7); natalizumab (n = 5); selective serotonin reuptake inhibitors (n = 8); tricyclic antidepressants n = 4); benzodiazepines (n = 4); voltage-dependent calcium channels inhibitors (n = 1); angiotensin-converting enzyme inhibitors (n = 1); statins (n = 1).
Table 1

| Parameters                  | Controls (n = 66) | MS patients (n = 30) | P*  |
|-----------------------------|-------------------|----------------------|-----|
| EDSS (0 to 10)              | —                 | 2.00 (1.50–3.13)     |     |
| Male/Female [n(%)]          | 16/50 (24%/76%)   | 7/23 (23%/77%)       |     |
| Age (years)                 | 35.50 (26.75–43.00) | 35.00 (28.25–40.25) | 0.613|
| BMI (Kg/m²)                 | 26.48 (22.11–26.59) | 23.75 (21.98–28.43) | 0.931|
| Waist circumference (cm)    | 90.00 (81.00–95.50) | 86.40 (80.75–96.00) | 0.436|
| SBP (mmHg)                  | 124.00 (112.00–134.00) | 115.00 (110.00–121.00) | 0.011|
| DBP (mmHg)                  | 78.00 (71.50–86.50) | 72.50 (69.00–77.00)  | 0.001|
| Glycemia (mmol/L)           | 4.70 (4.51–5.10)  | 4.76 (4.16–5.70)     | 0.739|

Results are presented as median (inter quartile range). *Mann-Whitney test. EDSS, Expanded Disability Status Scale; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

2.4. Laboratory procedures

2.4.1. Blood samples collection

The blood samples were collected by venupuncture from control subjects and MS patients after an overnight fasting period, to EDTA containing tubes and to tubes without anticoagulant, in order to obtain plasma, buffy-coat and serum, and processed within 2 h of collection. Aliquots were immediately stored at −80°C until assayed.

2.4.2. Lipid profile

Serum lipids and lipoproteins analysis were performed in an auto-analyser (Cobas Mira S, Roche), using commercially available kits. Serum total cholesterol (TC) and triglycerides (TGs) concentrations were determined by enzymatic colorimetric tests (CHOD-PAP and GPO-PAP methods, Roche, respectively). HDL-c and LDL-c levels were measured by using enzymatic colorimetric tests, after selective separation of HDL and LDL fractions (Direct HDL-Cholesterol and Direct LDL-Cholesterol, Roche). Plasma concentration of Ox-LDL was evaluated by using a standard commercial enzyme-linked immunoassay (Oxidized LDL ELISA, Mercodia, eBioscience). HDL-c subpopulations were separated and quantified using a Lipoprint kit from QuantiMetrix Corp. (Redondo Beach, CA, USA). The assay involves a polyacrylamide gel electrophoresis assay and a complete Lipoprint System for data acquisition and quantification of Large, Intermediary and Small subpopulations of HDL. Serum paraoxonase activity of PON1 was assessed spectrophotometrically and expressed in nmol of p-nitrophenol/ml/min. In brief, paraoxonase activity was measured by adding serum to 1 mL Tris/HCl buffer (100 mmol/L, pH 8.0) containing 2 mmol/L CaCl₂ and 5.5 mmol/L paraoxon (O,O-diethyl-O-p-nitrophenylphosphate; Sigma Chemical Co). The rate of generation of p-nitrophenol was determined at 412 nm, 37°C, with the use of a continuously recording spectrophotometer (Beckman DU-68). Serum glucose levels were measured using a Glucose Oxidase commercial kit (Sigma, St. Louis, Mo, USA).

2.4.3. Inflammatory markers

Serum adiponectin (Mercodia, eBioscience) and TNF-α and VEGF (Quantikine®, R&D Systems, Minneapolis, USA) were evaluated by using standard commercial enzyme-linked immunoassays. CRP was evaluated by immunoturbidimetry, using commercially available kits (CRP [latex] High-Sensitivity, Roche Diagnostics).

2.5. Statistical analysis

Statistical analysis was performed by using the IBM Statistical Package for Social Sciences (SPSS) for Windows (SPSS, Inc., Chicago IL, version 19.0). The distribution of continuous variables was analyzed using Kolmogorov-Smirnov tests, to assess significant departures from Normality. Comparisons between groups were performed using Fisher’s exact test or Mann-Whitney U test. Adjustment of statistical differences for confounding factors was performed using analysis of covariance (ANCOVA). The association between categorical variables was analyzed using Pearson’s test. Bonferroni correction was applied to multiple comparisons. Statistical significance was accepted at P less than 0.05.

3. Results

3.1. Anthropometric data

The demographic and anthropometric data of patients and controls are summarized in Table 1. Thirty MS patients were recruited, 7 men and 23 women,
with a median age of 35.00 years old (inter quartile range: 28.25–40.25). All these patients were clinically evaluated using EDSS at the day of study enrollment, scoring a median value of 2.0 (1.50–3.13), which means, according to the scale, "minimal disability in 1 functional system" (the EDSS scores range from 0 [no disability] to 10 [death]). Patient's body mass index (BMI) had a median value of 23.75 (21.98–28.43) Kg/m², which is considered in the normal range ([18.5 to 25 Kg/m² – healthy weight) and no statistically significant difference was found considering this aspect in the control group (*P = 0.931). Similar situation was found regarding waist circumference and fasting glycemia. Patient's systolic (median of 115.00 mmHg [110.00–121.00]) and diastolic (median of 72.50 mmHg [69.00–77.00]) blood pressure values were significantly lower than in the control group (*P = 0.011 and *P = 0.001, respectively).  

3.2. Markers of lipid, inflammatory and angiogenic profile  

Table 2 summarizes the results obtained for all the markers of lipid, inflammatory and angiogenic profile which have been tested in the study. In terms of classic lipid profile, a significant difference was observed between patients and controls regarding: 1) the serum contents of triglycerides (TGs), which was higher in MS patients (median of 1.07 mmol/L [0.88–1.87], *P < 0.001); 2) the serum concentrations of LDL cholesterol (LDL-c), lower in MS patients group (median of 2.51 mmol/L [2.08–3.09], *P = 0.016). Despite these differences, particularly regarding patient’s triglyceridemia, it must be emphasized that it is within the range considered normal (< 3.9 mmol/L). No statistically significant differences were found between both groups’ levels of total cholesterol (Total-c) and HDL-cholesterol (HDL-c) (*P = 0.403 and *P = 0.854, respectively). Only 1 patient was under treatment with a statin (rosuvastatin, 5 mg per day).  

When looking for new biochemical markers of CVR, the apparently protective lipid profile described for MS patients changed notoriously: Ox-LDL is significantly higher (median of 91.63 U/L [74.47–116.99]) in patients (*P = 0.001); 2) the serum concentrations of LDL cholesterol (LDL-c), lower in MS patients group (median of 2.51 mmol/L [2.08–3.09], *P = 0.016). Despite these differences, particularly regarding patient’s triglyceridemia, it must be emphasized that it is within the range considered normal (< 3.9 mmol/L). No statistically significant differences were found between both groups’ levels of total cholesterol (Total-c) and HDL-cholesterol (HDL-c) (*P = 0.403 and *P = 0.854, respectively). Only 1 patient was under treatment with a statin (rosuvastatin, 5 mg per day).

When looking for new biochemical markers of CVR, the apparently protective lipid profile described for MS patients changed notoriously: Ox-LDL is significantly higher (median of 91.63 U/L [74.47–116.99]) in patients (*P = 0.001); even after adjustment for non-HDL-c plus Total-Chol/HDL-c and for Total-Chol/HDL-c: *P < 0.001 for the 3 adjustments.

Table 2 Markers of lipid, inflammatory and angiogenic profile of multiple sclerosis (MS) patients and age and sex-matched controls

| Parameters | Controls (n = 66) | MS patients (n = 30) | *P* |
|------------|------------------|--------------------|-----|
| Total-c (mmol/L) | 4.89 (4.49–5.14) | 4.57 (4.32–5.27) | 0.403 |
| TGs (mmol/L) | 0.86 (0.64–1.18) | 1.07 (0.88–1.87) | 0.000 |
| LDL-c (mmol/L) | 2.96 (2.57–3.50) | 2.51 (2.08–3.09) | 0.016 |
| HDL-c (mmol/L) | 1.46 (1.21–1.83) | 1.52 (1.31–1.69) | 0.854 |
| Non-HDL-c (mmol/L) | 3.33 (2.94–3.93) | 3.18 (2.71–3.79) | 0.611 |
| Total-Chol/HDL-c | 3.21 (2.73–4.02) | 3.19 (2.62–3.93) | 0.401 |
| LDL-c/HDL-c ratio | 1.96 (1.53–2.56) | 1.64 (1.21–2.35) | 0.041 |
| Total-c (mmol/L) | 4.89 (4.49–5.14) | 4.57 (4.32–5.27) | 0.403 |
| TGs (mmol/L) | 0.86 (0.64–1.18) | 1.07 (0.88–1.87) | 0.000 |
| LDL-c (mmol/L) | 2.96 (2.57–3.50) | 2.51 (2.08–3.09) | 0.016 |
| HDL-c (mmol/L) | 1.46 (1.21–1.83) | 1.52 (1.31–1.69) | 0.854 |
| Non-HDL-c (mmol/L) | 3.33 (2.94–3.93) | 3.18 (2.71–3.79) | 0.611 |
| Total-Chol/HDL-c | 3.21 (2.73–4.02) | 3.19 (2.62–3.93) | 0.401 |
| LDL-c/HDL-c ratio | 1.96 (1.53–2.56) | 1.64 (1.21–2.35) | 0.041 |
| Total-c (mmol/L) | 4.89 (4.49–5.14) | 4.57 (4.32–5.27) | 0.403 |
| TGs (mmol/L) | 0.86 (0.64–1.18) | 1.07 (0.88–1.87) | 0.000 |
| LDL-c (mmol/L) | 2.96 (2.57–3.50) | 2.51 (2.08–3.09) | 0.016 |
| HDL-c (mmol/L) | 1.46 (1.21–1.83) | 1.52 (1.31–1.69) | 0.854 |
| Non-HDL-c (mmol/L) | 3.33 (2.94–3.93) | 3.18 (2.71–3.79) | 0.611 |
| Total-Chol/HDL-c | 3.21 (2.73–4.02) | 3.19 (2.62–3.93) | 0.401 |
| LDL-c/HDL-c ratio | 1.96 (1.53–2.56) | 1.64 (1.21–2.35) | 0.041 |

Results are presented as median (inter quartile range). *Mann-Whitney test. CRP, C-reactive protein; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; Ox-LDL, oxidized low-density lipoprotein; PON1, paraoxonase 1; TGs, triglycerides; TNF-α, tumour necrosis factor alpha; Total-c, total cholesterol; VEGF, vascular endothelial growth factor. †P values adjusted for non-HDL-c plus Total-Chol/HDL-c.
TNF-α values were unchanged between groups ($P = 0.484$ and $P = 0.530$, respectively). C reactive protein (CRP) levels were higher in MS patients (median of 0.50 μg/mL [0.50–0.53]; $P < 0.001$), which seems to be balanced by an increased amount of adiponectin, an anti-inflammatory molecule, detected in the same group (median of 12.61 ng/mL [7.91–12.10]; $P = 0.023$). Despite not reaching statistical significance, VEGF levels tend to be higher (> 44%) in MS patients than in control population.

3.3. Ox-LDL is correlated with EDSS, VEGF, small HDL and triglycerides

In a correlation analysis, establishing a bridge between laboratorial determinations and patients clinical stage, as measured by the EDSS, a positive and significant correlation was found between EDSS score and Ox-LDL ($r = 0.458$; $P = 0.011$) and LDL-c ($r = 0.366$; $P = 0.050$) serum levels (Fig. 1(A)). Similar correlation was also found between LDL-c and Ox-LDL contents ($r = 0.742$; $P < 0.001$) (Fig. 1(B)).
Serum VEGF levels were also positively and significantly correlated with Ox-LDL ($r = 0.453; P = 0.014$) and LDL-c contents ($r = 0.459; P = 0.014$) (Fig. 2(A)). A similar relationship was established between LDL-c/HDL-c ratio and small HDL-c ($r = 0.388; P = 0.037$) and Ox-LDL ($r = 0.582; P = 0.001$) (Fig. 2(B)).

Other established correlations, in MS patients group, were the following: 1) Ox-LDL and TGs ($r = 0.456; P = 0.011$); 2) EDSS and total-c ($r = 0.404; P = 0.027$); 3) LDL-c and glycemia ($r = 0.453; P = 0.014$); 4) a negative and statistically significant correlation was defined between small HDL-c and adiponectin ($r = -0.359; P = 0.050$).

### 4. Discussion

In this paper, we have reported results indicating that MS patients could have an increased CVR, based on elevation of some aggressive and atherogenic molecules in serum, particularly Ox-LDL and small HDL-c. However, this risk profile is hidden behind an apparently normal classic lipid panel (despite the significant difference observed in terms of serum TGs contents, but within the normal range), reinforcing the importance of looking for some new biochemical markers of CVR in MS patients. In our study population, it was also possible to correlate those new lipid profile abnormalities with clinical staging, evaluated by the usage of the universal EDSS score, which raises the possibility of such aggressive molecules to be involved in the process of disease progression.

It is well known that cholesterol is an important component of myelin. Lipids, especially lipoproteins, are involved in the regulation of neural functions in the CNS through local mechanisms that are linked to systemic lipid metabolism [19,20]. Under normal and physiological conditions, high concentrations of HDL and LDL are present in CNS, as a result of transport across the brain-blood barrier (BBB) [21]. However, dyslipidemia can potentiate inflammatory processes at the vascular endothelium, lead to the production of adhesion molecules and to the recruitment of leukocytes [22,23]. The recruitment and extravasation of immune cells across the activated endothelium of the BBB is considered to be a critical step in MS pathogenesis. A significant amount of cerebral vascular endothelial dysfunction has been reported in MS [24], accompanied by some degree of cerebral hypoperfusion [25]. Weinstock-Guttman et al., studying a population of 492 MS patients, concluded that serum lipid profile had modest effects on disease progression. Worsening disability was associated with higher levels of LDL, total cholesterol and triglycerides, whereas higher levels of HDL were associated with minor levels of acute inflammatory activity, in magnetic resonance imaging (MRI) [11]. However (and even taking into account that our study did not focus on imagiological analysis), our data draw attention to the importance of measuring new markers of dyslipidemia (particularly Ox-LDL and small HDL), more reliably related with the disease and its progression, continuing to support the working hypothesis of thinking that the pro-inflammatory and thrombogenic mechanisms associated with an abnormal lipid profile could contribute to MS progression, through diverse processes at the BBB vascular endothelium. The relevance of “non-classic” markers of cardiovascular risk, such as oxidized LDL, has been increasingly demonstrated in young or adult subjects with coronary artery disease [26,27].

An important limitation of our study is sample size (only 30 patients were included and analyzed). Still, only 1 patient was under treatment with a statin, excluding the possible and meaningful interference of this kind of drugs in our results. Some studies of statin treatment in MS were performed, but they originated mixed results [28–33]. In a study of 30 MS patients, the treatment with simvastatin resulted in a significant reduction in the number and volume of contrast-enhancing lesions, on serial monthly MRI [28]. A post-hoc analysis of the interferon beta treated control arm of the SENTINEL study did not show any effect of statins on the following endpoints: adjusted annualized relapse rate, disability progression, number of contrast-enhancing lesions and number of new or enlarging T2-hyperintense lesions over 2 years [31]. The STayCIS study tried to assess the effect of statin treatment in slowing the conversion of clinical isolated syndromes to clinically definite MS, but it did not meet its primary endpoint (development of 3 or more new T2 lesions or 1 clinical relapse within 12 months) [32]. The SIM-COMBIN trial indicated that statin treatment did not provide benefit in MS patients on interferon beta [33]. According to our knowledge, this is the first study showing a strong correlation between EDSS score and Ox-LDL and LDL, suggesting a negative impact of LDL-c, and particularly of Ox-LDL, on EDSS. Those markers of early CVR may raise special attention for premature intervention, in order to prevent cardiovascular disease in MS patients. Lifestyle changes, including adoption of a healthier diet and regular ex-
exercise, providing improvement on serum lipid profile, may be beneficial for MS patients to improve their neurological condition. Early introduction of an anti-dyslipidemic drug, such as a statin, can be tested in the future, looking for an impact on new markers of cardiometabolic risk, such as those described in this paper.

It must be emphasized that these are young patients, in no way resembling the typical profile of atherosclerotic individuals seen in clinical practice – MS patients are not obese, they do not suffer from hypertension or diabetes and, if we only consider the classical lipid panel, they present normal-range values. The striking age and sex-matching between patients and control volunteers should be also noted. When compared with this control subjects, the young MS patients show an early unfavorable vascular risk profile, traduced in the presence of more aggressive and atherogenic blood particles, such as ox-LDL and small HDL. Patient’s angiogenic function also contributes for this risk raising mixture. VEGF may stimulate the formation of microvessels inside the atherosclerotic plaque (which may become disrupted and cause intraplaque hemorrhage), has a role on thrombus formation and significantly contributes for global cardiometabolic risk. We detected an elevation of patients’ VEGF levels, of about 44%, comparing to controls. This result didn’t reach statistical significance, but also contributes to draw attention to this molecule in MS patients in futures studies. Chronic inflammation is also an important player in raising vascular risk. In a study published in 2005, Soilu-Hänninen et al. verified that CRP levels, measured by a high-sensitivity technique, were similar in patients with MS and healthy controls, but higher during MS relapses than in remission ($p = 0.010$) [34]. They also verified that patients under treatment with interferon beta-1a had lower levels of serum CRP, comparing with those treated with placebo in the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study ($p = 0.035$). All patients included in our study were under treatment with disease modifying drugs (first line therapy) or natalizumab. Serum CRP levels were within the normal range for all of them, although values were higher (reaching statistical significance) than those found in healthy volunteers, reinforcing the concept of chronic inflammation being present in this clinical situation. This seemed to be balanced by a similar variation in the levels of adiponectin, which normally plays an anti-inflammatory role, as previously said. But this dynamic relationship deserves further investigation, in order to understand how these molecules interact and contribute for the global CVR in MS.

5. Conclusions

MS patients seem to present a profile indicative of an increased CVR, when compared with healthy subjects of well matched age and sex. The clinical activity of the disease (given by the EDSS score) was directly and significantly correlated with some markers of CVR, particularly Ox-LDL content, among other putatively good new markers that deserve further attention (small HDL subpopulation and VEGF). The early atherogenic risk found in this population should receive special attention and, in the future, after better understand the mechanisms involved and after better characterize the molecular players interacting, this issue might be enough to recommend early pharmacotherapeutic intervention to prevent premature development of cardiovascular disease in these patients.

Acknowledgments

This study was supported by the Portuguese Group for the Study of Multiple Sclerosis, through a grant received from Merck Serono.

Conflict of interest

The authors report no conflict of interest.

References

[1] World Health Organization: Atlas Multiple Sclerosis Resources in the World. Geneva, WHO 2008, http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf (accessed on 20 July 2012).
[2] Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: Risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727-39.
[3] Acevedo AR, Nava C, Arriada N, Violante A, Corona T. Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand. 2000;101(2):85-8.
[4] Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis: A population-based cohort study. Neuroepidemiology. 2010;35(4):267-74.
[5] Ranadive SM, Yan H, Weikert M, Lane AD, Linden MA, Baynard T, Motl RW, Fernhall B. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012;44(2):238-43.
[6] Merkelbach S, Haensch CA, Hemmer B, Koehler J, König NH, Ziemsen T. Multiple sclerosis and the autonomic nervous system. J Neurol. 2006;253 Suppl 1:i21-5.
Borghini, I., Barja, F., Pometta, D., James, R.W. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochem Biophys Acta. 1995; 1255(2):192-200.

Cybulsy, M.J., Jr. Gimbreon MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogen esis. Science. 1991; 251(4995):788-791.

Stokes, K.Y., Calahan, L., Hamric, C.M., Russell, J.M., Granger, D.N. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol. 2009;296(3):H689-97.

Minagar, A., Jy, W., Jimenez, J.J., Alexander, J.S. Multiple sclerosis as a vascular disease. Neurol Res. 2006;28(3):230-5.

De Keyser, J., Steen, C., Mostert, J.P., Koch, M.W. Hypoperfusion of the cerebral white matter in multiple sclerosis: Possible mechanisms and pathophysiological significance. J Cereb Blood Flow Metab. 2008;28(10):1645-51.

Huang, H., Ma, R., Liu, D., Liu, C., Ma, Y., Mai, W., Dong, Y. Oxidized low-density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease. Dis Markers. 2012 Oct 22. [Epub ahead of print].

Huang, Y., Hu, Y., Mai, W., Cai, X., Song, Y., Wu, Y., Dong, Y., Huang, H., He, Z., Li, W., Yang, Y., Rao, S. Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease. Dis Markers. 2011;31(5):295-301.

Vollmer, T., Key, L., Durkalski, V., Tynor, V., Corboy, J., Markovic-Plesce, S., Preiningerova, J., Rizzo, M., Singh, I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607-8.

Markovic-Plesce, S., Jewells, V., Speer, D. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2009;72(22):1965-6.

Sellner, J., Weber, M.S., Vollmar, P., Mattle, H.P., Hammer, B., Stüve, O. The combination of interferon-beta and HMGB-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon? CNS Neurosci Ther. 2010;16(6):362-73.

Rudick, R.A., Pace, A., Rani, M.R., Hyde, R., Panzara, M., Appachi, S., Shrock, J., Mauren, S.L., Calabresi, P.A., Confavreux, C., Galetta, S.L., Lublin, F.D., Radue, E.W., Ransohoff, R.M. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989-93.

Waubant, E., Pelletier, D., Mass, M., Cohen, J.A., Kita, M., Cross, A., Bar-Or, A., Vollmer, T., Racke, M., Stüve, O., Schwid, S., Goodman, A., Kachuck, N., Preiningerova, J., Weinstock-Guttman, B., Calabresi, P.A., Miller, A., Mokhtarani, M., Ikld, D., Murphy, S., Kopetskie, H., Ding, L., Rosenberg, E., Spencer, C., Zamvil, S.S. ITN STAYCIS Study Group; ITN020AI Study Management Team. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAYCIS study. Neurology. 2012;78(15):1171-8.

Sorensen, P.S., Lycke, J., Erälinna, J., Eland, A., Wu, X., Fredriksen, J.L., Ortau, A., Malmeström, C., Stenager, E., Sellebjerg, F., Sondergaard, H.B. SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): A placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691-701.

Soili-Hänninen, M., Koskinen, J.O., Laaksonen, M., Hänninen, A., Lütös, E.M., Waris, M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology. 2005;65(1):153-5.